3C疗法循证医学解读更新版演示文稿.ppt

* Ideally, advanced technology devices such as RT-CGM/CSII should have benefits not only in terms of clinical outcomes, but also for patient-reported outcomes (PROs)such as treatment satisfaction and health-related quality of life (HRQOL). Health-related quality of life is a criticaloutcome in its own right, and treatment satisfaction affects patient acceptance. The RT-CGM/CSII group gave significantly better ratings than the SMBG + CSII group for their glucose monitoring system’s glucose control efficacy, overall satisfaction, desire to switch, and willingness to recommend, and significantly worse ratings for interference with daily activities. The RT-CGM/CSII group gave significantly better ratings than the SMBG + CSII group for their insulin delivery system’s convenience and glucose control efficacy, overall satisfaction, desire to switch, and willingness to recommend. Real-time CGM/CSII users gave positive ratings of all system features. Conclusions: Users of the integrated RT-CGM/CSII system reported more benefits of treatment, higher treatment satisfaction and quality of life, and greater preference for this system than SMBG + CSII users. * 为什么3C疗法较单C疗法更有优势？ 实时血糖信息和趋势，更及时的信息获取和治疗调整 高低血糖报警让降糖更安心 CareLink软件全景展示多种数据，全面判断信息，综合管理疾病 * * * * 9401136-011 051506 * * Abstract Aims? To investigate the efficacy of sensor-augmented pump therapy vs. multiple daily injection therapy in patients with suboptimally controlled Type?1 diabetes. Methods? In this investigator-initiated multi-centre trial (the Eurythmics Trial) in eight outpatient centres in Europe, we randomized 83 patients with Type?1 diabetes (40 women) currently treated with multiple daily injections, age 18–65?years and HbA1c≥?8.2% (≥?66?mmol/mol) to 26?weeks of treatment with either a sensor-augmented insulin pump (n?=?44) (Paradigm? REAL-Time) or continued with multiple daily injections (n?=?39). Change in HbA1c between baseline and 26?weeks, sensor-derived endpoints and patient-reported outcomes w